Stay tuned to PXR: An orphan actor that may not be D-structive only to bone

Journal of Clinical Investigation

Volumn 115, Issue 1, 2005, Pages 32-34

  Holick, Michael F ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; CALCITRIOL; PREGNANE X RECEPTOR; XENOBIOTIC AGENT; CELL RECEPTOR; CYTOCHROME P450; STEROID MONOOXYGENASE; STEROID RECEPTOR; VITAMIN D; VITAMIN D 24 HYDROXYLASE; VITAMIN D 24-HYDROXYLASE;

BONE DEFECT; BONE DISEASE; BONE METABOLISM; CALCIUM METABOLISM; PRIORITY JOURNAL; REVIEW; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM; ANIMAL; BONE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; HUMAN; METABOLISM; NOTE;

ANIMALS; BONE AND BONES; BONE DISEASES; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, STEROID; STEROID HYDROXYLASES; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 13744258265     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200523995     Document Type: Review

References (20)

1. Schmid, F. 1967. Osteophthien bei antiepileptischer Dauerbehandlung. Fortschr. Med. 38:381-382.
2. Dent, C.E., Richens, A., Rowe, D.J.F., and Stamp, T.C.B. 1970. Osteomalacia with long-term anti-convulsant therapy in epilepsy. Br. Med. J. 4:69-72.
3. Gascon-Barré, M. 2004. Antiepileptic drugs and bone health. In Nutrition and bone health. B. Dawson-Hughes and M.F. Holick, editors. Humana Press. Totowa, New Jersey, USA. 647-666.
4. 3. Endocrinology. 129:2335-2344.
5. 3 in the dog. Am. J. Physiol. 251:G627-G635.
6. Hahn, T.J., Birge, S.J., Scharp, C.R., and Avioli, L.V. 1972. Phenobarbital-induced alterations in vitamin D metabolism. J. Clin. Invest. 51:741-748.
7. Wark, J.D., et al. 1979. Chronic diphenylhydantoin therapy does not reduce plasma 25-hydroxyvitamin D. Clin. Endocrinol. 11:267-274.
8. Holick, M.F. 2004. Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am. J. Clin. Nutr. 79:362-371.
9. Pascussi, J.M., et al. 2005. Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia. J. Clin. Invest. 115:177-186. doi:10.1172/JCI200521773.
10. 3 24-hydroxylase gene promoter and identification of two vitamin D-responsive elements. Biochim. Biophys. Acta. 1263:1-9.
11. Omdahl, J.L., Bobrovinkova, E.A., Choe, S., Dwivedi, P.P., and May, B.K. 2001. Overview of regulatory cytochrome P450 enzymes of the vitamin D pathway. Steroids. 66:381-389.
12. Lips, P., et al. 2001. A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of Raloxifene evaluation clinical trial. J. Clin. Endocrinol. Metab. 86:1212-1221.
13. Malabanan, A., Veronikis, I.E., and Holick, M.F. 1998. Redefining vitamin D insufficiency. Lancet. 351:805-806.
14. DeLuca, H.F., and Cantorna, M.T. 2001. Vitamin D: its role and uses in immunology. FASEB J. 15:2579-2585.
15. Polek, T.C., and Weigel, N.L. 2002. Vitamin D in prostate cancer. J. Androl. 23:9-17.
16. 3 is a negative endocrine regulator of the renin-angiotensin system. J. Clin. Invest. 110:229-238. doi:10.1172/JCI200215219.
17. 3. Diabetologia. 37:552-558.
18. McGrath, J. 2001. Does 'imprinting' with low prenatal vitamin D contribute to the risk of various adult disorders? Med. Hypotheses. 56:367-371.
19. Schwartz, G.G., Whitlatch, L.W., Chen, T.C., Lokeshwar, B.L., and Holick, M.F. 1998. Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3. Cancer Epidemiol. Biomarkers Prev. 7:391-395.
20. Chen, T.C., and Holick, M.F. 2003. Vitamin D and prostate cancer prevention and treatment. Trends Endocrinol. Metab. 14:423-430.